
![]() |
Formats:
|
||||||||||||||||||
Copyright © 2009 American Chemical Society Human Replication Protein A−Rad52−Single-Stranded DNA Complex: Stoichiometry and Evidence for Strand Transfer Regulation by Phosphorylation† ‡The Eppley Institute for Research in Cancer and Allied Diseases §Department of Biochemistry and Molecular Biology University of Nebraska Medical Center, 987696 Nebraska Medical Center, Omaha, Nebraska 68198-7696 College of Dentistry, University of Nebraska Medical Center, 40th and Holdrege, Lincoln, Nebraska 68583-0740*To whom correspondence should be addressed. Telephone: (402) 559-8578. Fax: (402) 559-3739. E-mail: gborgstahl/at/unmc.edu. These authors contributed equally to this workReceived April 2, 2009; Revised May 19, 2009. This is an open-access article distributed under the ACS AuthorChoice Terms & Conditions. Any use of this article, must conform to the terms of that license which are available at http://pubs.acs.org. Abstract ![]() The eukaryotic single-stranded DNA-binding protein, replication protein A (RPA), is essential in DNA metabolism and is phosphorylated in response to DNA-damaging agents. Rad52 and RPA participate in the repair of double-stranded DNA breaks (DSBs). It is known that human RPA and Rad52 form a complex, but the molecular mass, stoichiometry, and exact role of this complex in DSB repair are unclear. In this study, absolute molecular masses of individual proteins and complexes were measured in solution using analytical size-exclusion chromatography coupled with multiangle light scattering, the protein species present in each purified fraction were verified via sodium dodecyl sulfate−polyacrylamide gel electrophoresis (SDS−PAGE)/Western analyses, and the presence of biotinylated ssDNA in the complexes was verified by chemiluminescence detection. Then, employing UV cross-linking, the protein partner holding the ssDNA was identified. These data show that phosphorylated RPA promoted formation of a complex with monomeric Rad52 and caused the transfer of ssDNA from RPA to Rad52. This suggests that RPA phosphorylation may regulate the first steps of DSB repair and is necessary for the mediator function of Rad52. Double-strand breaks (DSBs)1 in chromosomal DNA are efficiently repaired by homologous recombination (HR) (1). The RAD52 epistasis group of proteins, including Rad51, Rad52, and replication protein A (RPA), performs the repair of DSBs by HR (2,3). Studies with Saccharomyces cerevisiae proteins (4−6) and with human proteins (7−10) demonstrated the importance of specific protein−protein contacts in controlling the functional interactions among Rad51, Rad52, and RPA. Rad52 acts as a mediator between RPA-coated ssDNA and Rad51 (11−13), and a similar function is also proposed for human BRCA2 protein (14). However, the molecular mechanisms for the delivery of Rad51 by mediators to RPA-coated ssDNA are not known in detail. RPA is the ubiquitous eukaryotic single-stranded DNA (ssDNA) binding protein that is composed of three subunits that have been named for their molecular masses in kilodaltons as RPA70, RPA32, and RPA14 (15,16). The heterotrimer is the main biological form of RPA (17,18) and is very stable when purified (19). RPA binds ssDNA more tightly than RNA or double-stranded DNA (dsDNA), prefers purines over pyrimidines (16), and has a 25−30-nucleotide footprint (20). RPA is composed of six oligonucleotide/oligosaccharide binding (OB) domains that bind ssDNA and/or participate in specific protein−protein interactions (21). RPA is also known to undergo a significant conformational change upon binding DNA (22,23) that appears to alter RPA’s structure in a way that facilitates interactions with other proteins and ssDNA. The exact signal(s) for the presence of single- or double-stranded DNA breaks in a cell is still poorly understood, but the ssDNA−RPA complex appears to be an important component (24). Once DSBs are sensed, several downstream HR repair effector proteins are phosphorylated (25). RPA is phosphorylated (and dephosphorylated) during the cell cycle, in response to DNA damage and during apoptosis (26−33). Most studies have focused on the phosphorylation of the N-terminus of RPA32, and up to nine Ser/Thr sites have been identified in the first 33 amino acids. Chromatin-associated fractions of RPA contain the phosphorylated forms of RPA32, and phosphorylation can cause the RPA heterotrimer to dissociate (34). RPA is known to be phosphorylated upon exposure of cultured human cells to UV or ionizing radiation (30,33). This DNA damage-induced phosphorylation is coincident with cell cycle arrest and loss of the ability of cell extracts to support DNA replication (33). It is known that ATM kinase, DNA-dependent protein kinase, and cyclin-Cdk phosphorylate RPA32 N-terminal residues (26,35,36). Recent studies have revealed new phosphorylation sites on RPA32 and RPA70 and that phosphorylation modulates the affinity of RPA for ssDNA (37−39). The localization of phosphorylated RPA (pRPA) to other DSB repair proteins, including Rad52, has been reported (24), and pRPA facilitates chromosomal DNA repair in cells (36). An improved interaction between RPA and Rad52 was observed by immunoprecipitation following hydroxyurea treatment (known to produce pRPA), and cell cycle regulators (like Chk1) are thought to lead to replacement of RPA with Rad51 and Rad52 during HR (40). These observations suggest that phosphorylation serves as an essential mechanism for modulating RPA’s activity, its quaternary structure, and its interactions with other proteins. Although the effects of pRPA on DNA replication and various DNA repair pathways have been studied (28), limited information about the regulation of the protein−protein and protein−DNA complexes involved in DSB repair by pRPA is available. Rad52 protein has three known activities in DSB repair (13,41). The first activity is early in the mechanism and involves the recruitment of Rad51 onto ssDNA that is coated with RPA at the break site. This is a well-characterized and essential function of Rad52 for the in vivo function of Rad51 in yeast (11) and appears to be a function that may overlap with BRCA2 protein in humans (42). The second activity is to anneal complementary ssDNA molecules that have RPA bound in the single-strand annealing pathway for DSB repair in regions of repetitive DNA sequences (43). This mutagenic pathway is stimulated when BRCA2 is deficient (44,45) and promotes genomic instability. The third activity is downstream of Rad51-mediated DNA strand exchange where Rad52 promotes the annealing of the displaced ssDNA strand to a second ssDNA strand (13,41). Rad52 has greater binding affinity for ssDNA than dsDNA (46,47) and appears to have two separate binding sites for each in the N-terminus of Rad52 (48). Studies have shown that Rad52 has a binding preference for 5′ or 3′ ssDNA ends, and ssDNA hypersensitivity to hydroxyl radical patterns suggests that four nucleotides are protected by Rad52 binding (49,50). Rad52 is capable of capping DNA termini, can protect DSBs from nuclease attack (46,49) after the ends are processed into ssDNA tails (51), and can promote ligation (49,52). Electron microscopy (EM) studies of S. cerevisiae and hRad52 have revealed formation of ring-shaped structures (9−13 nm in diameter), as well as higher-order aggregates (49,53−55). Structural and solution studies have demonstrated that the self-association domain in the N-terminal half of Rad52 is responsible for ring formation and that elements in the C-terminal half of the molecule participate in the formation of higher-order complexes of rings (56,57). Human Rad52 rings in EM analysis have been interpreted to be composed of seven subunits (56,57), whereas crystal structures of the N-terminal half of human Rad52 revealed an undecameric ring (58,59). The function of Rad52 multimers remains unclear, although multimerization appears to be important for nuclear localization (60). Singleton and co-workers speculated that ssDNA binds in a positively charged groove and wraps around the ring (59). The stoichiometry of RPA and Rad52 complexes and the effects of protein−protein interactions on DNA specificity and affinity are not well understood and are the topic of this study. Human RPA and Rad52 have specific interactions with each other (61−66). The interaction of Rad52 with RPA was shown to significantly increase the affinity of RPA for homopurine ssDNA in vitro (62) which is counterintuitive for Rad52’s mediator function. However, the effect of pRPA on Rad52 intermolecular interactions has not been explored. In this study, we explored the effects of pRPA on Rad52 protein−protein and DNA−protein complexes. We conducted a series of stoichiometry experiments with purified components in solution by measuring absolute molecular masses of individual proteins as well as DNA−protein complexes with analytical size-exclusion chromatography coupled with multiangle light scattering (SEC−MALS) (see refs (67) and (68) for reviews of the SEC−MALS methodology). Our results indicate that pRPA interacts differently with ssDNA and Rad52. It also reveals that the affinity of Rad52 for ssDNA increases when pRPA is part of the complex and indicates transfer of ssDNA from pRPA to Rad52. On the basis of these data, we propose a model for the initial steps in HR-based DSB repair. In these studies, we have also tested the relevance of the Rad52 ring model in DSB repair. The data reported indicate the importance of both pRPA and monomeric Rad52 in DSB repair in humans. Experimental Procedures Protein Purification, Phosphorylation, and ssDNA Rad52 proteins (57,62) and RPA proteins (69) were purified as described previously with the following modification. Bacterial cultures expressing recombinant RPA were supplemented with 100 μM ZnCl2. The protein concentrations were calculated using a Bradford assay (Bio-Rad) with bovine serum albumin as a standard. pRPA was prepared in vitro and purified as previously described and characterized (37,39). Briefly, RPA was purified as above and for phosphorylation, the RPA was dialyzed and mixed with HeLa extracts. The mixture was supplemented with an ATP regenerating system, ssDNA, and phosphatase inhibitors to inhibit phosphatase activity within the cell extracts. This reaction allows for endogenous kinases within the HeLa extract to phosphorylate RPA. Following incubation for 3 h at 30 °C, the hyperphosphorylated RPA was purified in a manner identical to that of recombinant RPA, mentioned above. The ionic strength of buffer solutions was optimized and kept as low as possible to support protein complex formation as well as protein solubility (see Figure 7 of ref (62)). Thus, RPA was dialyzed against buffer A [50 mM Tris (pH 7.8), 0.5% inositol, 2 mM EDTA, 2 mM 2-mercaptoethanol, and 150 mM KCl; note that the KCl concentration varied as specified], and Rad52 was dialyzed against buffer A with 200 mM KCl. The 3′-biotinylated synthetic 25mer oligonucleotide was designed based on a natural DNA gene sequence, using DNASTAR to minimize secondary structure and dimers, and was composed of the sequence GCTAGCTCAATTCATCGACAAACCT (MW = 7815 Da). Biotinylated oligonucleotide was dissolved in water, and the concentration was measured at OD260 using an extinction coefficient of 4.21 nM−1 cm−1. In Vitro Complex Formation We formed the ssDNA−RPA complex by mixing RPA and ssDNA at a 1:2 molar ratio in buffer A and incubating the mixture for 1 h on ice. We formed the ssDNA−Rad52 complex by mixing ssDNA and Rad52 in a 2:1 ratio in buffer A with 200 mM KCl and incubating the mixture for 1 h on ice. We formed the RPA−Rad52 complex by mixing RPA and Rad52 in a 1:2 ratio in buffer A with 175 mM KCl. For the ssDNA−RPA−Rad52 complex, the ssDNA−RPA complex was mixed first and incubated for 1 h on ice and then Rad52 was added at a 2:1 ratio (Rad52:RPA) in buffer A. The ssDNA−pRPA−Rad52 complex was formed following the same protocol. All protein−protein complexes were incubated on ice overnight before being analyzed. Size-Exclusion Chromatography with Multiangle Light Scattering (SEC−MALS) SEC−MALS experiments were performed at room temperature by loading 100−240 μg of protein sample on a Superose 6 10/300 GL column (Amersham Biosciences) with a bed volume of approximately 24 mL, an exclusion limit of 4 × 104 kDa, and an optimal separation range from 5 to 5 × 103 kDa. A flow rate of 0.3 mL/min was used, unless otherwise indicated, using an Agilent HPLC instrument. The column was eluted with buffer A. Downstream from the column, a UV detector (Agilent), a miniDAWN triple-angle light scattering detector (Wyatt Technology), and an Optilab DSP interferometric refractometer (IR, Wyatt Technology) were connected in series. The refractometer provided a continuous index of protein concentration. A dn/dc (refractive index increment) value of 0.185 mL/mg was used. Bovine serum albumin was used as an isotropic scatterer for detector normalization. The light scattered by a protein is directly proportional to its weight-average molecular mass and concentration. Therefore, molecular masses (MW) were calculated from the light scattering and IR concentration data using Astra. Error in SEC−MALS measurements can be caused by a relatively low concentration of some species, interdetector band broadening, or poor MW separation that results in polydispersity of the sample as it flows through the downstream detectors. A low concentration gives a lower light scattering signal and causes a spread in the derived MW data. The chromatograms from the LS and IR detectors do not overlay when there is polydispersity in the samples. Polydispersity is also indicated by the breadth and shape of the peaks in the chromatogram. The derived MW data will have a sloped appearance for polydisperse samples and can appear to grin or frown due to interdetector band broadening. Fractions (0.1 mL) collected were analyzed by sodium dodecyl sulfate−polyacrylamide gel electrophoresis (SDS−PAGE), chemiluminescent ssDNA detection, antiRad52 Western blotting, and/or electron microscopy. The relative areas of IR peaks were manually calculated. Chemiluminescence ssDNA Detection and UV Cross-Linking For each SEC−MALS peak, 1 μL of every fraction was dotted on a nylon membrane (0.45 μm, Invitrogen) and biotinylated ssDNA was detected by chemiluminescence (Chemiluminescent Nucleic Acid Detection Module, Pierce), according to the manufacturer’s protocol. In some experiments, ssDNA was cross-linked to protein via a 2 min exposure in a UV Stratalinker 1800, before SDS−PAGE separation and detection by chemiluminescence. Gel Mobility Shift Assays Individual DNA binding reaction mixtures (10 μL) containing 10 mM Tris (pH 7.5), 150 mM KCl, 1 mM DTT, 5% (v/v) glycerol, 100 fmol of ssDNA, and a varying amount of RPA (0−300 fmol) were incubated at room temperature for 20 min. Then 3 μL of DNA loading buffer [150 mM Tris (pH 6.8), 300 mM DTT, 0.1% bromophenyl blue, and 30% glycerol] was added to each reaction mixture, and the entire mixture was separated by electrophoresis at 70 V for ~45 min at 4 °C on native 4% agarose gels in 1× TAE buffer. The gels were transferred onto a positively charged nylon membrane and UV cross-linked for 1 min, and ssDNA was detected by chemiluminescence (using the Chemiluminescence EMSA kit from Pierce). SDS−PAGE Analysis and Rad52 Western Blots For each SEC−MALS peak, 10 μL of each fraction was mixed with 5 μL of SDS loading buffer [150 mM Tris-HCl (pH 6.8), 300 mM DTT, 6% SDS, 0.3% bromophenol blue, and 30% glycerol], boiled in a water bath for 3 min, briefly centrifuged, loaded on a NuPAGE 10% Bis-Tris gel (Invitrogen), and separated by SDS−PAGE. Duplicate gels were run. One was silver stained, and the other was analyzed by Western blotting. Proteins were transferred to a nitrocellulose membrane (Invitrogen) and probed with mouse anti-Rad52 antibody specific for human Rad52 residues 303−340 (antibody #207 as described in ref (62)). Electron Microscopy (EM) All protein peaks from SEC−MALS fractions that could possibly contain Rad52 were examined by EM. Only those samples that indicated clearly defined structures are discussed in the text and summarized in Table 1. Samples for EM were prepared by dilution to 2.0 μM in buffer A with 200 mM KCl. Samples were spread onto thin carbon films on 400 mesh carbon grids, stained with 1% uranyl acetate, and visualized by transmission electron microscopy using a Philips 410LS transmission electron microscope.
Results ssDNA−RPA−Rad52 Complex The molecular masses of purified RPA and Rad52 protein samples and their ssDNA complexes were measured by SEC−MALS analysis for direct molecular mass determination. With SEC−MALS, the intensity of light scattered is directly proportional to molecular mass, and when these are combined with protein concentration data provided by the interferometric refractometer, the absolute molecular mass can be determined for homogeneously separated species. The form of RPA relevant to DNA repair has ssDNA bound, so the effect of prebinding RPA with a short piece of ssDNA on the stoichiometry of a RPA−Rad52 complex was analyzed by SEC−MALS (Figure (Figure1).1
Our previous studies indicated that the RPA−Rad52 complex increased the affinity of RPA for ssDNA (62). Thus, to determine which protein partner is bound to the ssDNA in the complexes, the SEC fractions were treated with UV to cross-link protein to ssDNA and then separated by SDS−PAGE before the chemiluminescence detection of the biotin-labeled ssDNA. Control experiments show that both RPA70 and Rad52 can be cross-linked to ssDNA and are easily distinguishable in this assay (Figure (Figure1C).1 Effect of Phosphorylated RPA on the ssDNA−RPA−Rad52 Complexes Cellular RPA is phosphorylated in response to ionizing radiation, so a phosphorylated form of RPA is likely to be the active agent in HR-based DSB repair. Therefore, the effects of purified pRPA (Figure (Figure2A)2
Again, UV cross-linking was performed to determine which protein partner binds to the ssDNA in the complexes. Results were as follows. (1) For peak 1, no cross-linked ssDNA was detected (Figure (Figure2D,2 To help deconvolute the effects of phosphorylation and protein−protein interactions on ssDNA binding affinity, we measured the relative affinity of RPA and pRPA for oligonucleotides by a gel mobility shift assay. Previous studies had indicated that this purified form of pRPA had no difference in ssDNA binding to pyrimidine-rich sequences and decreased affinity for purine-rich ssDNA (39). Gel mobility shift assays with the mixed sequence 25mer oligomer used in these studies indicate that pRPA has a relative increase in ssDNA binding affinity over that of RPA (Figure (Figure2E).2 RPA−Rad52 Complex Alone To help decipher the effects of protein−protein interactions from those of protein−ssDNA interactions in the data given above, the stoichiometry of the RPA−Rad52 complex alone was studied. Rad52 binds Coomassie blue stain very well, causing a relative overestimation of its Bradford concentration relative to RPA; therefore, we used silver-stained gels loaded with various ratios of Rad52 to RPA to find that an approximate equimolar ratio of RPA to Rad52 was formed by mixing RPA and Rad52 in a 1:2 molar ratio (Figure (Figure3A,3
It is interesting to compare the collection of data from the three types of RPA−Rad52 complexes. Clearly, the breakdown of Rad52 rings to monomers is promoted by prebinding RPA to ssDNA. When the RI peak areas (dark black line) and molecular masses were compared, we observed that the 707 kDa aggregates in peak 1 of Figure Figure3B3 SEC−MALS of Individual Proteins As a control and validation of the SEC−MALS technique, the individual proteins and ssDNA−protein complexes were evaluated. Human RPA eluted as a single peak (Figure (Figure4A),4
Human Rad52 samples eluted primarily as a self-associated complex (Figure (Figure5A,5
To study the end binding capacity of Rad52, we performed gel mobility shift assays with 3′- and 5′-biotin-labeled ssDNA. Gel shifts indicated that as the amount of Rad52 increased and the complex formed, the chemiluminescent signal from the biotin on the ends was quenched by Rad52 binding (Figure 6 of the ). This quenching supports end binding by Rad52 under the conditions of this study. The 25mer ssDNA used was not long enough to cover the predicted footprint of the undecameric Rad52 ring (assuming four nucleotides per Rad52 monomer requires a 44mer). Also, since the ssDNA was in excess, the number of ssDNA ends was relatively large in our system. Therefore, to improve our understanding of the stoichiometry of binding of the ssDNA−Rad52 complex, two molar ratios were studied by SEC−MALS (1:1 and 11:1 ssDNA:ring ratios) using the 25mer (see Figures 8 and 9 of the ) and also using a 44mer ssDNA (see Figures 10 and 11 of the ). These results are discussed in the supplement and can be summarized as follows. Changing the length of the ssDNA had no effect on the complex, but changing the molar ratio did. At a 1:1 Rad52 ring:ssDNA molar ratio, one molecule of ssDNA was bound to the undecameric Rad52 ring (Table 2 of the , samples 2 and 4). When one ring is mixed with 11 ssDNA molecules, 9−12 ssDNA molecules were bound to the ring (Table 2 of the , samples 3 and 5). Taken together, these data indicate that the mode of ssDNA binding to Rad52 is mainly end binding and that the number of ssDNA molecules bound depends on the number of ssDNA ends available. Discussion The major finding of this study was the effect of phosphorylation of RPA on the ssDNA−RPA−Rad52 complex. Once DSBs are sensed, several downstream HR repair effector proteins are phosphorylated, including RPA. The phosphorylation of the N-terminus of RPA32 in response to DNA-damaging agents has been well documented (30,33). The form of pRPA used here has been well characterized and is known to be phosphorylated at several more sites other than the N-terminus of RPA32 (37,39), including the C-terminus of RPA70. These extra sites had no significant effect on nucleotide excision repair (37,39), and the formation of these new phosphorylation sites by other DNA-damaging agents such as ionizing radiation has not been investigated. Also the effect of this phosphorylated form of RPA on HR-based DSB repair was unknown, so the ssDNA binding and stoichiometry of the ssDNA−pRPA−Rad52 complex were studied in detail here. We found that the ssDNA−pRPA complex efficiently formed a stable complex with monomeric Rad52. Also, Rad52 can be cross-linked with ssDNA but only when RPA is phosphorylated, indicating that the affinity of Rad52 for ssDNA had increased in the pRPA−Rad52 complex. This could also be the result of pRPA causing a conformational change in Rad52 that makes it able to cross-link to ssDNA. This observation provides direct evidence of RPA handing the ssDNA to monomeric Rad52 and a demonstration that this reaction is regulated by the phosphorylation of RPA. A monomeric form of Rad52, as well as the multimeric ring form of Rad52, appears to be relevant to the function of Rad52 in DSB repair. Our earlier experiments with a phosphorylation mimic in which eight Ser/Thr residues on the N-terminus of RPA32 were mutated to Asp indicated that there was no measurable effect on the RPA−Rad52 complex (62). Taken together, these results indicate that perhaps the newly identified residues that are phosphorylated on RPA70 may also be important in DSB repair. These observations require further study. In addition, the stoichiometry of Rad52 rings revealed that purified, full-length, wild-type Rad52 forms a self-associated complex composed of a ring of 11 Rad52 monomers (Figure (Figure5A,5 Our data also shed some light on the formation of a complex of ssDNA, RPA, and Rad52. The number of RPA molecules in a human cell has been estimated to be between 4 × 104 and 2.4 × 10572−74, and it is predicted that any ssDNA present in the cell would be rapidly saturated by RPA binding (75). Thus, when Rad52 encounters a ssDNA-tailed substrate at the DSB repair site, it probably already has RPA bound. Experimentally, we observed that RPA and Rad52 form a relatively weak and heterogeneous complex when ssDNA is absent and that the complexes formed become more homogeneous when RPA has ssDNA bound. The major species for the ssDNA−RPA−Rad52 complex incorporated a monomeric form of Rad52. Experimentally, the ssDNA−RPA−Rad52 complex was much more stable than the RPA−Rad52 complex and was easier to measure. Interestingly, RPA is probably in excess over Rad52 in human cells. Although this ratio has not been directly measured in human cells, GFP-tagged proteins in S. cerevisiae indicate that there is 4−6 times more RPA than Rad52 (76) per yeast cell. Therefore, since the RPA in a cell is likely to be bound to ssDNA and in excess over Rad52, it is unlikely that Rad52 retains its ring structure at the DSB repair site. The disruption of the Rad52 ring structure may be caused by a conformational change in Rad52 structure or may indicate that residues in the so-called self-association region (residues 125−185) are also involved in binding RPA as well as the previously identified RPA binding site that includes residues 220−280 (61,62). This stoichiometry for the RPA−Rad52 complex at the repair site, which was directly measured here, was previously proposed for S. cerevisiae proteins on the basis of the detection of a ssDNA−RPA−Rad52 complex in gel mobility shift assays (77). While our studies confirm this stoichiometry, they also provide the molecular mass of the complex, which cannot be measured with native gels. These observations are also in agreement with the work of Navadgi and co-workers, who observed monomeric complexes of human Rad51, Rad52, and ssDNA (78). A Model for the Early Steps in Homologous Recombination-Based DSB Repair The main conclusions of this study are that the active form of Rad52 is monomeric, Rad52 forms a monomeric complex with RPA, and complex formation is promoted when RPA has ssDNA bound and is phosphorylated. Finally, phosphorylation of RPA enhances Rad52’s ability to bind ssDNA through either an induced conformational change, an increase in binding affinity, or both. Based on these observations, we propose the following model for the initial steps of HR-based DSB repair. After the DSB is formed (Figure (Figure6A)6
Acknowledgments We are grateful to the staff at Wyatt Technology Corp. for their helpful advice; in particular, we thank Andy Meyer and William Wittbold for useful discussions. We thank Doba Jackson and Uffe H. Mortensen for helpful discussions, Jeff Lovelace and Kerry Brader for technical assistance, and Tom Barger for assistance with samples at the University of Nebraska Medical Center Core Electron Microscopy Research Facility. Notes †This work was supported by the U.S. Army Medical Research and Materiel Command under Contract DAMD17-98-1-8251 (G.E.O.B.), American Cancer Society Grant RSG-02-162-01-GMC (G.E.O.B.), and National Cancer Institute Eppley Cancer Center Support Grant P30CA036727. Supporting Information Available Additional experimental procedures, results, and discussion. This material is available free of charge via the Internet at http://pubs.acs.org. Footnotes 1Abbreviations: RPA, replication protein A; pRPA, phosphorylated RPA; RPA70, 70 kDa subunit of RPA; RPA32, 32 kDa subunit of RPA; RPA14, 14 kDa subunit of RPA; ssDNA, single-stranded DNA; dsDNA, double-stranded DNA; DSBs, double-stranded DNA breaks; HR, homologous recombination; UV, ultraviolet; LS, light scattering; IR, interferometric refractometer; ELISA, enzyme-linked immunosorbent assay; SEC−MALS, size-exclusion chromatography with multiangle light scattering. bi900564k_si_001.pdf(765K, pdf) References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||
Trends Biochem Sci. 1995 Oct; 20(10):387-91.
[Trends Biochem Sci. 1995]Annu Rev Genet. 2004; 38():233-71.
[Annu Rev Genet. 2004]Mutat Res. 2000 Jun 30; 451(1-2):257-75.
[Mutat Res. 2000]J Biol Chem. 1997 Nov 7; 272(45):28194-7.
[J Biol Chem. 1997]Nature. 1998 Jan 22; 391(6665):407-10.
[Nature. 1998]Crit Rev Biochem Mol Biol. 1999; 34(3):141-80.
[Crit Rev Biochem Mol Biol. 1999]Annu Rev Biochem. 1997; 66():61-92.
[Annu Rev Biochem. 1997]Nucleic Acids Res. 2000 Sep 1; 28(17):3354-60.
[Nucleic Acids Res. 2000]Exp Cell Res. 2000 Feb 1; 254(2):321-7.
[Exp Cell Res. 2000]EMBO J. 1988 Apr; 7(4):1211-8.
[EMBO J. 1988]Biochem J. 2005 Nov 1; 391(Pt 3):473-80.
[Biochem J. 2005]Nature. 2000 Nov 23; 408(6811):433-9.
[Nature. 2000]J Biol Chem. 1997 May 9; 272(19):12634-41.
[J Biol Chem. 1997]EMBO J. 1994 May 1; 13(9):2114-23.
[EMBO J. 1994]J Biol Chem. 1999 May 28; 274(22):15556-61.
[J Biol Chem. 1999]Mol Cell. 2008 Feb 29; 29(4):510-6.
[Mol Cell. 2008]EMBO J. 2006 Nov 29; 25(23):5539-48.
[EMBO J. 2006]J Biol Chem. 2003 Oct 31; 278(44):42729-32.
[J Biol Chem. 2003]Oncogene. 2006 Sep 25; 25(43):5864-74.
[Oncogene. 2006]Microbiol Mol Biol Rev. 1999 Jun; 63(2):349-404.
[Microbiol Mol Biol Rev. 1999]J Biol Chem. 1996 Aug 2; 271(31):18996-9000.
[J Biol Chem. 1996]J Biol Chem. 2008 Oct 24; 283(43):29077-85.
[J Biol Chem. 2008]J Mol Biol. 2002 Aug 2; 321(1):133-48.
[J Mol Biol. 2002]J Biochem Biophys Methods. 2003 Jun 30; 56(1-3):95-116.
[J Biochem Biophys Methods. 2003]Methods Mol Biol. 2004; 261():113-8.
[Methods Mol Biol. 2004]J Biol Chem. 2001 May 11; 276(19):15876-80.
[J Biol Chem. 2001]J Mol Biol. 2002 Aug 2; 321(1):133-48.
[J Mol Biol. 2002]J Biol Chem. 1994 Apr 15; 269(15):11121-32.
[J Biol Chem. 1994]Biochemistry. 2005 Jun 14; 44(23):8428-37.
[Biochemistry. 2005]Biochemistry. 2005 Jun 14; 44(23):8438-48.
[Biochemistry. 2005]J Mol Biol. 2002 Aug 2; 321(1):133-48.
[J Mol Biol. 2002]J Mol Biol. 2002 Aug 2; 321(1):133-48.
[J Mol Biol. 2002]Biochemistry. 2005 Jun 14; 44(23):8438-48.
[Biochemistry. 2005]Mol Cell Biol. 1993 Dec; 13(12):7222-31.
[Mol Cell Biol. 1993]EMBO J. 1994 May 1; 13(9):2114-23.
[EMBO J. 1994]Biochemistry. 2005 Jun 14; 44(23):8428-37.
[Biochemistry. 2005]Biochemistry. 2005 Jun 14; 44(23):8438-48.
[Biochemistry. 2005]J Mol Biol. 2002 Aug 2; 321(1):133-48.
[J Mol Biol. 2002]Mol Cell. 2002 Aug; 10(2):359-71.
[Mol Cell. 2002]Proc Natl Acad Sci U S A. 2002 Oct 15; 99(21):13492-7.
[Proc Natl Acad Sci U S A. 2002]Curr Biol. 2000 Mar 23; 10(6):337-40.
[Curr Biol. 2000]EMBO J. 2000 Aug 1; 19(15):4175-81.
[EMBO J. 2000]J Mol Biol. 1998 Dec 11; 284(4):1027-38.
[J Mol Biol. 1998]Proc Natl Acad Sci U S A. 1988 Apr; 85(8):2523-7.
[Proc Natl Acad Sci U S A. 1988]J Biol Chem. 1993 Apr 5; 268(10):7147-54.
[J Biol Chem. 1993]Biochemistry. 1995 Feb 14; 34(6):2058-64.
[Biochemistry. 1995]Nature. 2003 Oct 16; 425(6959):737-41.
[Nature. 2003]J Biol Chem. 1996 Aug 2; 271(31):18996-9000.
[J Biol Chem. 1996]J Mol Biol. 2002 Aug 2; 321(1):133-48.
[J Mol Biol. 2002]